DrugCite
Search

PROVENGE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Provenge Adverse Events Reported to the FDA Over Time

How are Provenge adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Provenge, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Provenge is flagged as the suspect drug causing the adverse event.

Most Common Provenge Adverse Events Reported to the FDA

What are the most common Provenge adverse events reported to the FDA?

Fatigue
104 (2.06%)
Chills
93 (1.84%)
Asthenia
88 (1.74%)
Anaemia
78 (1.54%)
Pyrexia
71 (1.4%)
Fall
65 (1.29%)
Nausea
65 (1.29%)
Dehydration
64 (1.27%)
Malaise
61 (1.21%)
Hypotension
57 (1.13%)
Infusion Related Reaction
55 (1.09%)
Show More Show More
Disease Progression
54 (1.07%)
Haemoglobin Decreased
54 (1.07%)
Back Pain
53 (1.05%)
Cerebrovascular Accident
52 (1.03%)
Pain
51 (1.01%)
Vomiting
51 (1.01%)
Dyspnoea
49 (.97%)
Confusional State
47 (.93%)
Decreased Appetite
45 (.89%)
Weight Decreased
45 (.89%)
Arthralgia
42 (.83%)
Prostate Cancer Metastatic
42 (.83%)
Atrial Fibrillation
40 (.79%)
Chest Pain
38 (.75%)
Transient Ischaemic Attack
38 (.75%)
Myocardial Infarction
37 (.73%)
Neoplasm Progression
36 (.71%)
Adverse Event
35 (.69%)
Device Related Infection
35 (.69%)
Pneumonia
35 (.69%)
Urinary Tract Infection
35 (.69%)
Dizziness
34 (.67%)
Haematuria
34 (.67%)
Metastases To Bone
32 (.63%)
Prostate Cancer
31 (.61%)
Thrombocytopenia
31 (.61%)
Constipation
30 (.59%)
Death
30 (.59%)
Hospitalisation
30 (.59%)
Renal Failure Acute
29 (.57%)
Muscular Weakness
28 (.55%)
Oedema Peripheral
28 (.55%)
Syncope
28 (.55%)
Pleural Effusion
26 (.51%)
Blood Pressure Increased
25 (.49%)
Cardiac Failure Congestive
25 (.49%)
Hyponatraemia
25 (.49%)
Atelectasis
24 (.47%)
Deep Vein Thrombosis
24 (.47%)
Sepsis
24 (.47%)
Blood Alkaline Phosphatase Increase...
23 (.45%)
Platelet Count Decreased
23 (.45%)
Pulmonary Oedema
22 (.43%)
Blood Glucose Increased
21 (.42%)
Diarrhoea
21 (.42%)
Disorientation
21 (.42%)
Pain In Extremity
21 (.42%)
Tremor
21 (.42%)
Influenza Like Illness
20 (.4%)
Loss Of Consciousness
20 (.4%)
Renal Failure
20 (.4%)
Bone Pain
19 (.38%)
Prostatic Specific Antigen Increase...
19 (.38%)
Hypoaesthesia
18 (.36%)
Hypoxia
18 (.36%)
Mental Status Changes
18 (.36%)
Myalgia
18 (.36%)
Pulmonary Embolism
18 (.36%)
Subdural Haematoma
18 (.36%)
Haematocrit Decreased
17 (.34%)
Haemorrhage Intracranial
17 (.34%)
Heart Rate Increased
17 (.34%)
Oxygen Saturation Decreased
17 (.34%)
Tachycardia
17 (.34%)
Blood Pressure Decreased
16 (.32%)
Hypertension
16 (.32%)
Insomnia
16 (.32%)
Bacteraemia
15 (.3%)
Hydronephrosis
15 (.3%)
Malnutrition
15 (.3%)
Metastases To Central Nervous Syste...
15 (.3%)
Unresponsive To Stimuli
15 (.3%)
Cough
14 (.28%)
Infection
14 (.28%)
Somnolence
14 (.28%)
Staphylococcal Bacteraemia
14 (.28%)
Delirium
13 (.26%)
Gastrointestinal Haemorrhage
13 (.26%)
General Physical Health Deteriorati...
13 (.26%)
Spinal Cord Compression
13 (.26%)
Thrombosis
13 (.26%)
Anxiety
12 (.24%)
Aspartate Aminotransferase Increase...
12 (.24%)
Atrial Septal Defect
12 (.24%)
Bronchitis
12 (.24%)
Carotid Artery Stenosis
12 (.24%)
Chronic Obstructive Pulmonary Disea...
12 (.24%)
Fluid Overload
12 (.24%)
Hypokalaemia
12 (.24%)
Lymphadenopathy
12 (.24%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Provenge, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Provenge is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Provenge

What are the most common Provenge adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Provenge, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Provenge is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Provenge According to Those Reporting Adverse Events

Why are people taking Provenge, according to those reporting adverse events to the FDA?

Prostate Cancer Metastatic
627
Prostate Cancer
45
Product Used For Unknown Indication
1

Drug Labels

LabelLabelerEffective
ProvengeDendreon Corporation23-JUN-11

Provenge Case Reports

What Provenge safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Provenge. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Provenge.